Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topical Multiple Ascending Dose Study for PF-06423264

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02778477
Recruitment Status : Terminated (Preliminary analysis of accrued data failed to indicate any meaningful pharmacodynamic response.)
First Posted : May 20, 2016
Last Update Posted : June 21, 2017
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
The current study is the first clinical trial proposed with PF-06423264. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of multiple ascending doses of PF-06423264 to healthy adult subjects with or without oily skin.

Condition or disease Intervention/treatment Phase
Normal Healthy Drug: PF-06423264 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 65 participants
Allocation: Randomized
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-06423264 Administered Topically To Sequential Cohorts Of Healthy Subjects With And Without Oily Skin
Actual Study Start Date : May 23, 2016
Actual Primary Completion Date : May 23, 2017
Actual Study Completion Date : May 23, 2017

Arm Intervention/treatment
Experimental: Part A_Cohort 1_Active
Multiple ascending dose of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part A_Cohort 1_Placebo
Multiple dose of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part A_Cohort 2_Active
Multiple ascending dose of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part A_Cohort 2_Placebo
Multiple dose of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part A_Cohort 3_Active
Multiple ascending dose of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part A_Cohort 3_Placebo
Multiple dose of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part A_Cohort 4_Active
Multiple ascending dose of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part A_Cohort 4_Placebo
Multiple dose of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part A_Cohort 5_Active
Multiple ascending dose of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part A_Cohort 5_Placebo
Multiple dose of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part A_Cohort 6_Active
Multiple ascending dose of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part A_Cohort 6_Placebo
Multiple dose of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part A_Cohort 7_Active
Multiple ascending dose of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part A_Cohort 7_Placebo
Multiple ascending dose of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part B_Cohort 1_Active
Multiple doses of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part B_Cohort 1_Placebo
Multiple doses of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator

Experimental: Part B_Cohort 2_Active
Multiple doses of PF-06423264
Drug: PF-06423264
Multiple ascending dose of PF-06423264

Placebo Comparator: Part B_Cohort 2_Placebo
Multiple doses of placebo
Other: Placebo
Multiple dose of placebo
Other Name: Placebo comparator




Primary Outcome Measures :
  1. Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) or other safety concerns [ Time Frame: Baseline (Day 0) up to 28 days after last dose of study medication ]

    Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements.

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.


  2. Number of Participants with Draize-like scoring and clinical observation [ Time Frame: Baseline (Day 1) up to Day 42+3 ]
    Modified Draize-like scoring and clinical observation. Severity estimated by clinical signs and scoring; ranged 0-4: 0= No reaction visible, 1= Trace reaction - barely perceptible pinkness, 2= Mild reaction - readily visible pinkness, 3= Moderate reaction - definite redness, 4= Strong to severe reaction - very intense redness.

  3. Number of Participants With Clinical Laboratory Abnormalities [ Time Frame: Baseline (Day 0) up to 28 days after last dose ]
    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick [urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin], microscopy [urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous [urine mucus and leucocytes]).

  4. Number of Participants With Abnormal Electrocardiogram (ECG) [ Time Frame: Baseline (Day 0) up to 28 days after last dose ]
    Criteria for potential clinical concern in ECG parameters: Maximum QTcF interval (Fridericia's Correction) in range of 450 to less than 480 msec, maximum QTc interval increase from baseline in range of 30 to less than 60 msec and >=60 msec.

  5. Number of Participants With Categorical Vital Signs Data [ Time Frame: Baseline (Day 0) up to 28 days after last dose ]
    Number of participants with maximum increase from Baseline in sitting SBP and DBP of greater than or equal to 30 mmHg was reported.


Secondary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) for PF-06423264 [ Time Frame: 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24 hours post dose on Day 1 and 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 36, and 48 hours post dose on Day 14 ]
    Maximum Observed Plasma Concentration (Cmax)

  2. Time to Reach Maximum Observed Concentration for PF-06423264 [ Time Frame: 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24 hours post dose on Day 1 and 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 36, and 48 hours post dose on Day 14 ]
    Time to Reach Maximum Observed Plasma Concentration (Tmax)

  3. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for PF-06423264 [ Time Frame: 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24 hours post dose on Day 1 and 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 36, and 48 hours post dose on Day 14 ]
    Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 12 hours.

  4. Plasma Decay Half-Life (t1/2) for PF-06423264 [ Time Frame: 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24 hours post dose on Day 1 and 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 36, and 48 hours post dose on Day 14 ]
    Plasma Decay Half-Life (t1/2)

  5. Apparent Volume of Distribution (Vz/F) for PF-06423264 [ Time Frame: 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24 hours post dose on Day 1 and 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 36, and 48 hours post dose on Day 14 ]
    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

  6. Apparent Total Body Clearance (CL/F) for [ Time Frame: 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24 hours post dose on Day 1 and 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 36, and 48 hours post dose on Day 14 ]
    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after apparent total body clearance is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

  7. Observed Accumulation Ratio (Rac) for PF-06423264 [ Time Frame: 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24 hours post dose on Day 1 and 0, 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 36, and 48 hours post dose on Day 14 ]
    Rac was calculated as, area under the curve from time zero to end of dosing interval on Day Y (AUCtau) divided by area under the curve from time zero to end of dosing interval on Day X(AUCtau).

  8. change from baseline in sebum lipid components and sebum excretion [ Time Frame: Baseline (Day 0) up to 16 days after last dose of study medication ]
    change from baseline in sebum lipid components and sebum excretion as assessed with Sebutape strips and Sebumeter measurements on the forehead of subjects with oily skin



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males and female of non-childbearing potential;
  • Body Mass Index 17.5-35.5 kg/m2;
  • Body weight >50 kg;

Exclusion Criteria:

  • Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02778477


Locations
Layout table for location information
Belgium
Pfizer Clinical Research Unit
Brussels, Belgium, B-1070
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT02778477    
Other Study ID Numbers: B7561002
2014-003736-39 ( EudraCT Number )
First Posted: May 20, 2016    Key Record Dates
Last Update Posted: June 21, 2017
Last Verified: June 2017